Gotistobart Long Term Extension (LTE) Study
NCT07659379 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2026-06-23
Summary
This LTE study will examine the long-term overall survival and safety of gotistobart in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
- DRUG
-
ONC-392 will be given following parent trial
Sponsors & Collaborators
-
OncoC4, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-01
- Primary Completion
- 2036-07-01
- Completion
- 2037-01-01
- FDA Drug
- Yes
More Related Trials
-
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
NCT04446351 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
NCT03616834 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
NCT06431594 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
NCT07050641 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
NCT07080619 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05474859 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
NCT07737509 ·Status: RECRUITING
-
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours
NCT07594028 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
NCT01407380 ·Status: COMPLETED ·Phase: PHASE1
-
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
NCT07060989 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
NCT05101096 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors
NCT07665970 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
NCT05821777 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NCT05617859 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
NCT06235983 ·Status: COMPLETED ·Phase: PHASE1
-
Study of LM-302 in Patients With Advance Solid Tumors
NCT05161390 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
NCT05983523 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
NCT06258408 ·Status: RECRUITING ·Phase: PHASE1
-
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
NCT00052273 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
NCT04059887 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
NCT05586321 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma
NCT06384248 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2